Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT05083169
Title A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (MajesTEC-3)
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Janssen Research & Development, LLC
Indications

multiple myeloma

Therapies

Bortezomib + Daratumumab + Dexamethasone

Daratumumab + Teclistamab

Daratumumab + Dexamethasone + Pomalidomide

Age Groups: adult | senior
Covered Countries USA | ITA | FRA | ESP | DEU | CAN | BEL


No variant requirements are available.